Under AGDUFA, fees collected, appropriated, and not obligated at the end of a fiscal year remain available to the FDA for use in future fiscal years. These funds are referred to as carryover balances. The operations in FY 2010 resulted in a reduction of the carryover balance by a total of $214,759, for a year-end carryover balance of $2,247,937.
Numbers may not add due to rounding to the nearest dollar.
Please note that the balances in Table 3 reflect the cumulative cash from the beginning to the end of each fiscal year, and net cash collected during each fiscal year for all cohort years. The numbers do not include any accounts receivable. Therefore these numbers for FY 2009 and FY 2010 are different from the numbers on page 3, which reflect total new collections for the cohort years only.
Collections Ceilings and Surplus
Under AGDUFA, if the cumulative collections for FY 2009 through 2011, plus the amount of fees estimated to be collected in FY 2012, are in excess of the fee amounts specified in the Appropriations Act, the cumulative amount in excess of appropriations may be kept and used to reduce the fee rates when fees for FY 2013 are set. The following table depicts FY 2010 fee collections realized (the same as Total Collections in the table on page 3), collection ceilings specified in the Appropriations Act, and the cumulative difference.
Statement of Generic NEW Animal Drug User Fees Collected, Collections
Ceiling, and Amounts to Offset Future Collections
As of September 30, 2010
Amount to Offset Future Collections
Balance to be Offset in a Subsequent Fiscal Year
Additional FY 2010 cohort year fees collected subsequent to September 30, 2010 will be reported in the FY 2011 financial report.
Reserves and Balance Available for Allocation
Table 5 provides a summary of carryover balances as of September 30, 2010, and anticipated claims on those balances.
The only claim on the carryover balance is for prudent operations that require a reserve be kept aside for other potential refunds. For that purpose a total of $100,000 is being set aside. That leaves a total of $2,147,937 available for allocation. This is enough to fund estimated FY 2011 operations dependent upon user fee revenue for approximately 5 months.
Summary Statement of Carryover Balance
As of September 30, 2010
Status of Carryover Funds
Reserve for Future Collection Offset
Reserve for Refunds
Available for Allocation
TOTAL Carryover Balance
Next Section: Total Cost of the Process for the review of Animal Drug Applications